What is Evommune 's financing expense on warrant issuance?

Evommune (EVMN) reported financing expense on warrant issuance of $150 in Q4 2025.

What does financing expense on warrant issuance mean?

Costs incurred specifically in connection with the issuance of warrants, often treated as financing expenses. This highlights the friction costs associated with securing capital through equity-linked derivative instruments.

Evommune EVMN Financing Expense On Warrant Issuance

Financing Expense On Warrant Issuance at other companies

NovaGold ResourcesNG

$0-100%

PrecigenPGEN

$0-100%

Oruka Therapeutics, Inc.ORKA

$2.52M-75.7%

Navan, Inc. NAVN

$0-100%

NextNavNN

-$2.25M—

LCI IndustriesLCII

$0-100%

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept meha:FinancingExpenseOnWarrantIssuance.

The official record: Evommune ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's financing expense on warrant issuance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's financing expense on warrant issuance?: Evommune (EVMN) reported financing expense on warrant issuance of $150 in Q4 2025.
What does financing expense on warrant issuance mean?: Costs incurred specifically in connection with the issuance of warrants, often treated as financing expenses. This highlights the friction costs associated with securing capital through equity-linked derivative instruments.